cs0159

Obesity

Shanghai Jiao Tong University School of MedicineN/AActive

D

26/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 59/ 100

Competitive context

574 Active assets in the Obesity cohort.

Asset / Sponsor	Phase	Rating
vi-0521 VIVUS LLC	Phase 4	BBB
Tirzepatide LABORATORIOS INDUFAR	Phase 4	BBB
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Phase 4	BBB
Phentermine Russell McCulloh, MD	Phase 4	BBB
Deoxycholic Acid University of California, San Diego	Phase 4	BBB

View all 50 →

Same molecule, other indications

cs0159 is also rated in:

primary biliary cholangitisDormant

BB

Indicative ·

68 / 100

primary sclerosing cholangitisDormant

B

Indicative ·

58 / 100

metabolic dysfunction-associated steatohepatitisDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.